Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Low Immunoglobulin G and Low Lymphocyte-Monocyte Ratio at the End of Treatment Predict Early Progression in Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4459.

https://doi.org/10.1182/blood-2024-201850

Published: 2024

Journal Articles

Short Diagnosis to Treatment Interval Is Associated with Poor Outcomes in Relapse or Refractory Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3090.

https://doi.org/10.1182/blood-2024-201328

Published: 2024

Journal Articles

Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis

Mahmoud R. Gaballa, Thomas G Martin, Nobuhiro Tsukada, Kazuhito Suzuki, Hirono Iriuchishima, Emilie Chalayer, Vincent Camus, Maria Magdalena Alcala Peña, Anna Furlan, Max Christian Georg Hubmann, Wolfgang Ulrich Knauf, Christina Tekle, Ani Minasyan, Chunfu Qiu, Meral Beksac

Blood (2024) 144 (Supplement 1): 2411.5.

https://doi.org/10.1182/blood-2024-200165

Published: 2024

Journal Articles

Gnri (Geriatric Nutritional Risk Index) in Multiple Myeloma

Kohei Sato, Kazuhito Suzuki, Riku Nagao, Tadahiro Gunji, Masaharu Kawashima, Hideki Uryu, Mamiko Momoki, Hiroto Ishii, Mitsuji Katori, Susumu Tanoue, Atsushi Katsube, Hiroki Yokoyama, Takeshi Saito, Kaichi Nishiwaki, Shingo Yano

Blood (2024) 144 (Supplement 1): 1939.

https://doi.org/10.1182/blood-2024-203587

Published: 2024

Journal Articles

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

Blood (2024) 144 (Supplement 1): 4731.

https://doi.org/10.1182/blood-2024-199282

Published: 2024

Journal Articles

The Role of High-Dose Regimens Followed By Autologous Stem Cell Transplantation for Salvage Chemotherapy-Sensitive DLBCL Patients

Mamiko Momoki, Atsushi Katsube, Masaharu Kawashima, Kazuhito Suzuki, Ryoko Fukushima, Tadahiro Gunji, Hiroto Ishii, Hideki Uryu, Kaichi Nishiwaki, Shingo Yano

Blood (2023) 142 (Supplement 1): 7063.

https://doi.org/10.1182/blood-2023-178631

Published: 2023

Journal Articles

Prospective Comparison Study of Prognostic Value of MRD Detected By 8-Color MFC (EuroFlow-NGF) and NGS in Patients with Multiple Myeloma in ASCT Setting

Blood (2021) 138 (Supplement 1): 3946.

https://doi.org/10.1182/blood-2021-146441

Published: 2021

Journal Articles

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, MD PhD, Hiroshi Handa, MD PhD, Takayuki Saitoh, MD PhD, Kazutaka Sunami, MD PhD, Tadao Ishida, MD PhD, Kenshi Suzuki, MD PhD, Tomoko Narita, MD, Shinsuke Iida, MD PhD, Yuichi Nakamura, MD PhD, Kazuhito Suzuki, MD, Noriko Nishimura, MD PhD, Hirokazu Murakami, MD PhD, Kazuyuki Shimizu, MD

Blood (2019) 134 (Supplement_1): 3085.

https://doi.org/10.1182/blood-2019-125390

Published: 2019

Journal Articles

A New Prognostic Index for Waldenström Macroglobulinemia Based on a Multicenter Retrospective Study of the Japanese Society of Myeloma

Blood (2018) 132 (Supplement 1): 5320.

https://doi.org/10.1182/blood-2018-99-111649

Published: 2018

Journal Articles

Tumor-Lysis Syndrome in Relapsed or Refractory Multiple Myeloma Patients Treated with Proteasome Inhibitors

Kazuhito Suzuki, MD, Kaichi Nishiwaki, MD, Tadahiro Gunji, MD, Mitsuji Katori, MD, Rika Hosoba, MD, Kei Hirano, MD, Hidekazu Masuoka, Shingo Yano, MD PhD

Blood (2018) 132 (Supplement 1): 5631.

https://doi.org/10.1182/blood-2018-99-114822

Published: 2018

Journal Articles

Clinical Significance of Reactivation of Salivary HHV-6 and HHV-7 in Multiple Myeloma Treated with Novel Agents

Kazuhito Suzuki, MD, Shingo Yano, MD, Nobuyuki Kobayashi, MD PhD, Yoji Ogasawara, MD, Takaki Shimada, MD, Katsuki Sugiyama, MD, Takeshi Saito, MD, Shinobu Takahara, MD, Kazuhiro Kondo, MD PhD, Hiroyuki Yanagisawa, MD PhD, Noriko Usui, MD, Keisuke Aiba, MD

Blood (2016) 128 (22): 5633.

https://doi.org/10.1182/blood.V128.22.5633.5633

Published: 2016

Journal Articles

A Retrospective Comparison of Once-Daily Prolonged-Release Tacrolimus Versus Twice-Daily Tacrolimus in Allogeneic Bone Marrow Transplantation from Unrelated Donors

Shingo Yano, Takeshi Saito, MD, Hiroki Yokoyama, MD, Tomohito Machishimia, MD, Takaki Shimada, MD, Yuichi Yahagi, MD PhD, Shinobu Takahara, MD, Yoji Ogasawara, MD PhD, Katsuki Sugiyama, MD, Jiro Minami, MD, Yutaro Kamiyama, MD, Atsushi Katsube, MD, Noriyuki Morikawa, MD, Kazuhito Suzuki, MD, Yumiko Inui, MD, Noriko Usui, Keisuke Aiba, MD, PhD

Blood (2014) 124 (21): 5867.

https://doi.org/10.1182/blood.V124.21.5867.5867

Published: 2014

Journal Articles

High Thymidine Kinase Activity and CD5 Positivity Predict Poor Prognosis Of DLBCL Treated With R-CHOP

Kazuhito Suzuki, M.D., Yasuhito Terui, M.D., Ph D, Masahiro Yokoyama, MD, Noriko Nishimura, M.D., Ph D, Naoko Tsuyama, M.D., Kengo Takeuchi, MD, PhD, Noriko Usui, M.D., Ph D, Keisuke Aiba, M.D., Ph D, Kiyohiko Hatake, M.D., Ph D

Blood (2013) 122 (21): 5075.

https://doi.org/10.1182/blood.V122.21.5075.5075

Published: 2013

Journal Articles

Prognostic Value of High Thymidine Kinase Activity in Previously Untreated Diffuse Large B-Cell Lymphoma Treated by R-CHOP

Kazuhito Suzuki, MD, Yasuhito Terui, MD, PhD, Noriko Nishimura, MD, Yuko Mishima, Sakura Sakajiri, MD, Masahiro Yokoyama, MD, Naoko Tsuyama, MD, Kengo Takeuchi, MD, Keisuke Aiba, MD, PhD, Kiyohiko Hatake, MD, PhD

Blood (2012) 120 (21): 1541.

https://doi.org/10.1182/blood.V120.21.1541.1541

Published: 2012

Journal Articles

Soluble Interleukin-2 Receptors (sIL-2R) Is An Independent Prognostic Factor for Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP

Noriko Nishimura, MD, PhD, Masahiro Yokoyama, MD, Kengo Takeuchi, MD, Naoko Tsuyama, MD, Eriko Nara, MD, Kazuhito Suzuki, MD, Kenji Nakano, MD, Kyoko Ueda, MD, Yuko Mishima, MD, Sakura Sakajiri, MD, Shunji Takahashi, MD, PhD, Yasuhito Terui, MD, PhD, Kiyohiko Hatake

Blood (2011) 118 (21): 2678.

https://doi.org/10.1182/blood.V118.21.2678.2678

Published: 2011

Journal Articles

Prognostic Value of C-Reactive Protein, Lactase Dehydrogenase and Anemia in Recurrent or Refractory Malignant Lymphoma,

Kazuhito Suzuki, MD, Yasuhito Terui, MD, PhD, Yuko Mishima, MD, Eriko Nara, MD, Kenji Nakano, MD, Kyoko Ueda, MD, Noriko Nishimura, MD, Sakura Sakajiri, MD, Masahiro Yokoyama, MD, Shunji Takahashi, MD, Kiyohiko Hatake

Blood (2011) 118 (21): 3659.

https://doi.org/10.1182/blood.V118.21.3659.3659

Published: 2011

Journal Articles

RCHOP Therapy Overcome Gastric Diffuse Large B Cell Lymphoma without Surgery

Yuko Mishima, MD, Yasuhito Terui, MD, PhD, Masahiro Yokoyama, MD, Sakura Sakajiri, MD, PhD, Noriko Nishimura, MD, PhD, Kenji Nakano, MD, Eriko Nara, MD, Kazuhito Suzuki, MD, Kentaro Nasu, MD, Shunji Takahashi, MD, PhD, Kengo Takeuchi, MD, PhD, Kiyohiko Hatake, MD, PhD

Blood (2010) 116 (21): 1760.

https://doi.org/10.1182/blood.V116.21.1760.1760

Published: 2010

Journal Articles

Soluble Human Interleukin-2 Receptor (SIL-2R) as a Potential Predictor for Central Nervous System Relapse In Patients with Diffuse Large B-Cell Lymphoma In Rituximab Era: A 4.4-Year Follow up Analysis.

Noriko Nishimura, MD, PhD, Masahiro Yokoyama, MD, Kengo Takeuchi, MD, PhD, Eriko Nara, MD, Kenji Nakano, MD, Kentaro Nasu, MD, Kazuhito Suzuki, MD, Kyoko Ueda, MD, Yuko Mishima, MD, Sakura Sakajiri, MD, PhD, Shunji Takahashi, MD, PhD, Yasuhito Terui, MD, PhD, Kiyohiko Hatake, MD, PhD

Blood (2010) 116 (21): 2814.

https://doi.org/10.1182/blood.V116.21.2814.2814

Published: 2010

Journal Articles

Non-Gastric Advanced MALT Lymphoma Demonstrated Worse Prognosis Than Gastric MALT Lymphoma Even Treated by Rituximab-Combined chemotherapy.

Kyoko Ueda, MD, Yasuhito Terui, MD, PhD, Masahiro Yokoyama, MD, Sakura Sakajiri, Yuko Mishima, MD, Noriko Nishimura, MD, PhD, Kenji Nakano, Eriko Nara, Kazuhito Suzuki, Kentaro Nasu, Shunji Takahashi, MD, PhD, Kengo Takeutchi, MD, PhD, Kiyohiko Hatake, MD, PhD

Blood (2010) 116 (21): 2815.

https://doi.org/10.1182/blood.V116.21.2815.2815

Published: 2010

NARROW

Low Immunoglobulin G and Low Lymphocyte-Monocyte Ratio at the End of Treatment Predict Early Progression in Diffuse Large B-Cell Lymphoma

Short Diagnosis to Treatment Interval Is Associated with Poor Outcomes in Relapse or Refractory Diffuse Large B-Cell Lymphoma

Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis

Gnri (Geriatric Nutritional Risk Index) in Multiple Myeloma

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

The Role of High-Dose Regimens Followed By Autologous Stem Cell Transplantation for Salvage Chemotherapy-Sensitive DLBCL Patients

Prospective Comparison Study of Prognostic Value of MRD Detected By 8-Color MFC (EuroFlow-NGF) and NGS in Patients with Multiple Myeloma in ASCT Setting

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

A New Prognostic Index for Waldenström Macroglobulinemia Based on a Multicenter Retrospective Study of the Japanese Society of Myeloma

Tumor-Lysis Syndrome in Relapsed or Refractory Multiple Myeloma Patients Treated with Proteasome Inhibitors

Clinical Significance of Reactivation of Salivary HHV-6 and HHV-7 in Multiple Myeloma Treated with Novel Agents

A Retrospective Comparison of Once-Daily Prolonged-Release Tacrolimus Versus Twice-Daily Tacrolimus in Allogeneic Bone Marrow Transplantation from Unrelated Donors

High Thymidine Kinase Activity and CD5 Positivity Predict Poor Prognosis Of DLBCL Treated With R-CHOP

Prognostic Value of High Thymidine Kinase Activity in Previously Untreated Diffuse Large B-Cell Lymphoma Treated by R-CHOP

Soluble Interleukin-2 Receptors (sIL-2R) Is An Independent Prognostic Factor for Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP

Prognostic Value of C-Reactive Protein, Lactase Dehydrogenase and Anemia in Recurrent or Refractory Malignant Lymphoma,

RCHOP Therapy Overcome Gastric Diffuse Large B Cell Lymphoma without Surgery

Soluble Human Interleukin-2 Receptor (SIL-2R) as a Potential Predictor for Central Nervous System Relapse In Patients with Diffuse Large B-Cell Lymphoma In Rituximab Era: A 4.4-Year Follow up Analysis.

Non-Gastric Advanced MALT Lymphoma Demonstrated Worse Prognosis Than Gastric MALT Lymphoma Even Treated by Rituximab-Combined chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only